<DOC>
	<DOCNO>NCT00006056</DOCNO>
	<brief_summary>OBJECTIVES : I . Determine efficacy unrelated donor hematopoietic stem cell transplantation treatment patient life threaten hemophagocytic disorder . II . Determine rate disease free survival , incidence graft failure , incidence graft versus host disease patient undergoing treatment regimen .</brief_summary>
	<brief_title>Pilot Study Unrelated Donor Hematopoietic Stem Cell Transplantation Patients With Life Threatening Hemophagocytic Disorders</brief_title>
	<detailed_description>PROTOCOL OUTLINE : Patients receive oral busulfan twice day day -9 -6 ; cyclophosphamide IV 1 hour day -5 -2 ; etoposide IV 4 hour day -5 -3 ; anti-thymocyte globulin IV twice day day -2 -1 day 1 2 . Patients undergo allogeneic hematopoietic stem cell transplantation day 0 . Filgrastim ( G-CSF ) administer subcutaneously begin day 1 continue blood count recover . Patients receive graft versus host disease prophylaxis methotrexate IV day 1 , 3 , 6 , 11 cyclosporine IV 1-4 hour ( orally patient resume eat ) every 12 hour ( every 8 hour pediatric patient ) start prior day -3 continue 1 year . Patients follow day 28 100 , 6 month 1 year , annually 5 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Lymphohistiocytosis , Hemophagocytic</mesh_term>
	<mesh_term>Chediak-Higashi Syndrome</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Patients diagnose follow active stable , nonactive/quiescent , hemophagocytic disorder : Hemophagocytic lymphohistiocytosis ( HLH ) Fever great 38.5 degree Celsius Splenomegaly ( great 3 cm costal margin ) Hemophagocytosis bone marrow spleen lymph node Disease may confirm positive family history No evidence malignancy Hypertriglyceridemia and/or hypofibrinogenemia Fasting triglyceride least 2.0 mmol/L least 3 standard deviation normal age Fibrinogen great 1.5 g/L great 3 standard deviation normal Cytopenia ( affect least 2 3 lineage peripheral blood ) Hemoglobin le 9.0 g/L Platelet count le 100,000/mm3 Xlinked lymphoproliferative disorder ( XLP ) Two maternally related male manifest least one follow XLP phenotype : Fulminant infectious mononucleosis Dysgammaglobulinemia Malignant lymphoma/lymphoproliferative disorder Aplastic anemia Lymphoid granulomatosis/vasculitis OR A maternally related male establish XLP kindred strong genetic ( RFLP ) linkage XLP locus ChediakHigashi syndrome Partial oculocutaneous albinism ( hair , skin , eye ) Frequent bacterial infection Large peroxidase positive granule leukocytes peripheral blood bone marrow Positive family history parental consanguinity supportive diagnosis May enter accelerated phase define follow : Lymphadenopathy Pancytopenia Histiocytes hemophagocytosis bone marrow , lymph node , liver , spleen Viral associate hemophagocytic syndrome ( VAHS ) Relapsed prior therapy supportive care Diagnostic criterion HLH No hemophagocytic disorder secondary underlying malignancy Patients 35 year age must hematopoietic stem cell donor one following : HLA A B identical OR Single HLA A B serologic mismatch DRB1 identity OR HLA A B serologic identity single DRB1 mismatch Patients 36 55 year age must hematopoietic stem cell donor one following : HLA A B HLA DRB1 identical OR Single HLA A B serologic mismatch DRB1 identity Patients receive umbilical cord blood must unrelated donor two antigen HLA A , B , DRB1 mismatch Patient Characteristics Performance status : Karnofsky 70100 % OR Age le 16 year : Lansky 50100 % Life expectancy : Not severly limit another disease Hepatic : SGOT le 3 time normal Bilirubin le 2.5 mg/dL Renal : Creatinine normal OR Creatinine clearance glomerular filtration rate great 50 % normal Cardiovascular : If symptomatic , ventricular ejection fraction must great 40 % must improve exercise OR Shortening fraction normal echocardiogram Pulmonary : If symptomatic , DLCO great 45 % predict ( correct hemoglobin ) In child unable perform pulmonary function testing , oxygen saturation must great 95 % Other : HIV negative No significant active infection</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2003</verification_date>
	<keyword>Chediak-Higashi syndrome</keyword>
	<keyword>X-linked lymphoproliferative syndrome</keyword>
	<keyword>disease-related problem/condition</keyword>
	<keyword>familial erythrophagocytic lymphohistiocytosis</keyword>
	<keyword>genetic disease dysmorphic syndrome</keyword>
	<keyword>graft versus host disease</keyword>
	<keyword>hematologic disorder</keyword>
	<keyword>hemophagocytic lymphohistiocytosis</keyword>
	<keyword>histiocytosis</keyword>
	<keyword>immunologic disorder infectious disorder</keyword>
	<keyword>primary immunodeficiency disease</keyword>
	<keyword>rare disease</keyword>
	<keyword>virus-associated hemophagocytic syndrome</keyword>
</DOC>